Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated Arthritis

JENNIE URSUM, MIGNON A.C. van der WEIJDEN, DIRKJAN van SCHAARDENBURG, AREND P.A. PRINS, BEN A.C. DIJKMANS, JOS W.R. TWISK, JAKOB B.A. CRUSIUS and IRENE E. van der HORST-BRUINSMA
The Journal of Rheumatology July 2010, 37 (7) 1431-1438; DOI: https://doi.org/10.3899/jrheum.090913
JENNIE URSUM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIGNON A.C. van der WEIJDEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIRKJAN van SCHAARDENBURG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AREND P.A. PRINS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BEN A.C. DIJKMANS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOS W.R. TWISK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAKOB B.A. CRUSIUS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRENE E. van der HORST-BRUINSMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ie.vanderhorst@vumc.nl
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. In rheumatoid arthritis (RA), many genetic markers, such as the shared-epitope (SE) alleles, are described in association with radiographic progression, but limited data are available on undifferentiated arthritis (UA). We investigated whether single-nucleotide polymorphisms (SNP) and haplotypes in immune response genes and HLA class II alleles are associated with radiographic progression in patients with early UA.

Methods. Progression of radiographic damage was determined in white Dutch patients with early UA after 2 years of followup. Severe progression was defined as an increase in Sharp/van der Heijde Score ≥ 5 points after 2 years of followup. The remainder was classified as mild. These SNP were genotyped by Taqman technology: tumor necrosis factor (TNF) −1031, −863, −857, −308, −238; lymphotoxin-α (LTA) +368, +252; interleukin 10 (IL10) −2849, −1082, −819; IL1A −889, IL1B −31, +3953; and IL1RN +2018. Carriage of SE alleles and HLA-DQA1*05-DQB1*02 haplotype was established. These markers were analyzed in relation to radiographic progression.

Results. Forty-eight out of 151 patients with early UA had severe radiographic progression. Severe radiographic progression was associated with an increased carrier frequency of SE alleles (OR 5.12, 95% CI 2.0–13.1, p < 0.001) and IL10 GGC haplotype (OR 2.8, 95% CI 1.4–5.8, p = 0.003). Mild radiographic progression was associated with the HLA-DQA1*05-DQB1*02 haplotype (OR 0.3, 95% CI, 0.1–0.8, p = 0.013) and with allele TNF −308A (OR 0.4, 95% CI, 0.2–0.9, p = 0.02).

Conclusion. The SE and the IL10 GGC haplotype are associated with severe progression of radiographic damage, in contrast to the DQA1*05-DQB1*02 haplotype and the TNF −308A allele, which are associated with mild radiographic progression in early UA.

  • UNDIFFERENTIATED ARTHRITIS
  • RADIOGRAPHIC DAMAGE
  • SINGLE-NUCLEOTIDE POLYMORPHISM
  • HLA CLASS II ALLELES

The progress of rheumatoid arthritis (RA) is characterized by a large variation in severity of inflammation and joint destruction. Joint damage often begins in the early stages of the disease1. Among patients with early arthritis there is a large group that cannot be classified into any established disease category2,3. The term “undifferentiated arthritis” (UA) was introduced to distinguish these unclassifiable arthritides from RA and other inflammatory rheumatic diseases. The frequency of UA in early arthritis cohorts ranges from 20% to 45%3 and UA can result in severe radiographic damage4,5. Of the patients with UA studied in Jansen, et al, 42% showed radiographic progression with an increase in Sharp-van der Heijde score (SHS) of at least 10 points within 1 year4. In contrast to RA, in which associations with single-nucleotide polymorphisms (SNP) have been extensively studied, fewer data are available on the genetic characteristics of patients with UA6–9.

The major histocompatibility complex (MHC) class II alleles, referred to as the shared-epitope (SE) alleles, contribute to 30%–50% of the genetic predisposition to RA10,11: HLA-DRB1*0401, *0404, *0405, *0408, *0101, *1001, and *1402. Moreover, these SE alleles contribute to the development of antibodies against cyclic citrullinated peptide (ACPA)7 and are associated with a worse radiographic outcome in RA12,13. In contrast with SE, HLA-DRB1*03 is more frequently present in the ACPA-negative patients with RA compared to ACPA-positive patients (OR 1.6, 95% CI 1.2–2.1) and is associated with a less severe disease14.

Apart from MHC class II alleles, SNP in genes coding for cytokines such as tumor necrosis factor-α (TNF), lymphotoxin-α (LTA), interleukin 1α (IL1A), IL1B, and the natural IL-1 receptor antagonist IL1RN play a pivotal role in the regulation of inflammation and seem to be important in the onset and progression of RA as well as UA.

TNF-α is a proinflammatory cytokine with a key function in the pathogenesis of RA15. Excessive production of TNF-α can incite synovial inflammation and proliferation as well as degradation of articular cartilage and bone, which causes joint damage. Patients with RA receiving anti-TNF treatment have a large decrease in disease activity and have significantly less radiographic progression compared to a placebo group16. The carrier frequency of the TNF −308A allele is associated with an increase in TNF-α concentrations in peripheral blood mononuclear cells cultured with T cell activators17.

LTA (formerly TNF-ß), a homolog of TNF-α, has similar biological activity as TNF-α and shares one of its receptors18. Therefore LTA also might be a susceptibility gene for RA and for UA. The TNF and LTA genes are arranged in tandem and map within the MHC centromeric to HLA-B and telomeric to the MHC class III genes.

Other potential candidates in the onset of UA are polymorphisms at the IL1 family loci IL1A, IL1B, and IL1RN. The activity of IL-1, which initiates and perpetuates inflammatory and destructive processes in the rheumatoid joint19, is normally balanced by endogenous inhibitors, e.g., IL-1ra20,21. It is known that an imbalance between IL-1 and IL-1ra may be a predisposing factor for RA20, most likely reflected by homozygosity for the allele 2 of the IL1RN 86-bp variable number of tandem repeats, which is in strong linkage disequilibrium with IL1RN +2018C allele22. A relation between radiographic progression and SNP at the IL1 cluster in RA was also demonstrated23,24.

The antiinflammatory cytokine IL-10 is negatively correlated with the progression of joint destruction in RA25. The IL10 −2849 promoter polymorphism is associated with autoantibody production and subsequent joint damage in RA26. Also, IL10 −592CC and IL10 −1082GG have been associated with more severe radiographic damage only in patients who are ACPA-negative27, while another study showed opposite results28.

We investigated whether SNP in cytokine genes associated with arthritis as well as the presence of SE alleles and the DQA1*05-DQB1*02 haplotype were associated with the progression of radiographic damage in patients with UA.

MATERIALS AND METHODS

The study population consisted of patients with early UA who were included in the Early Arthritis Cohort (EAC) of the Jan van Breemen Institute, a large rheumatology clinic in Amsterdam, The Netherlands. Since 1995, newly referred patients are included and followed prospectively in the EAC if they are aged ≥ 18 years, have peripheral arthritis in ≥ 2 joints, and a symptom duration of ≤ 3 years. Patients were excluded if they had been treated with a disease-modifying antirheumatic drug (DMARD) or if they had spondyloarthropathy, reactive arthritis, crystal-induced arthropathy, systemic lupus erythematosus, Sjögren’s syndrome, or osteoarthritis. The choice of treatment after inclusion was made by the rheumatologist. All included patients were Dutch and white, defined as patients with at least 3 Dutch white grandparents. The local Ethics Committee approved the study protocol, and all patients gave written informed consent.

Measurements

Data were collected on demographics, symptom duration, and disease activity in 28 joints (DAS28)29. The laboratory assessments included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IgM-rheumatoid factor (IgM-RF), and ACPA. Radiographs of the hands and feet were also made. Data on demographics and symptom duration were collected at baseline and data on the other variables were collected annually (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of 151 Dutch white patients with undifferentiated arthritis. Data are mean (SD), median with interquartile range, or frequencies.

Dependent variable

Radiographic damage was assessed with the SHS30 by 2 experienced rheumatologists who were blinded to the other variables and had a good intraclass correlation coefficient of 0.95. Severe progression was defined as an increase of the SHS of at least 5 points between baseline and 2 years of followup31. The remainder was classified as mild progression. After 2 years of followup, patients who fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA32 were classified as having RA, and the remainder were classified as UA.

Genotyping

Genomic DNA was extracted from EDTA blood samples using a standard method. Genotyping of promoter SNP was performed at positions −1031 (db SNP ID: rs1799964), −863 (rs1800630), −857 (rs1799724), −308 (rs1800629), and −238 (rs361525) in the TNF gene and of intronic SNP at positions +252 (rs909253) and +368 (rs746868) in the LTA gene. Further, we studied IL1 family genes at position −889 (rs1800587) within the promoter of the IL1A gene, at position −31 in the promoter region (rs1143627), and another at position +3953 in exon 5 (rs1143634) of the IL1B gene and intron 2 SNP IL1RN +2018 (rs419598). Additionally, we studied IL10 promoter SNP IL10 −2849 (rs6703630), IL10 −1082 (rs1800896), and IL10 −819 (rs1800871).

SNP were genotyped with Taqman 5’ allelic discrimination technology (Applied Biosystems Inc., Foster City, CA, USA)33. Sequences of primers, fluorescent reporter dye-labeled probes, and reaction conditions were recorded.

Carriage of 1 or 2 HLA-DRB1 SE copies (i.e., SE+) was inferred from HLA-DQA1-DQB1 haplotypes in very strong linkage disequilibrium with HLA-DRB1 alleles in whites34,35. Polymerase chain reaction-amplified exon 2 DQA1 and DQB1 amplicons were generated for genotyping in a combined single-stranded conformation polymorphism/heteroduplex assay by a semiautomated electrophoresis and gel staining method on the Phastsystem (Amersham Pharmacia Biotech, Uppsala, Sweden). The method has been validated using a panel of reference DNA against the Dynal Allset+ high-resolution typing kit (Dynal A.S., Oslo, Norway)33.

These haplotypes could be reliably characterized in homozygous and heterozygous states33: HLA-DQA1*03-DQB1*0301 and DQA1*-03-DQB1*0302 (both DR4-related SE), DQA1*0101-DQB1*0501 (DR1 and DR10-related SE), and DQA1*0501-DQB1*02 (strictly DRB1*0301-related).

The SE+ status as established by the DQA1 and DQB1 PCR-SSCP/HD assay was validated in 87 established patients with RA by high-resolution sequence-based typing of HLA-DRB1 exon 2. To contain the SE, the HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410, and *1001 alleles were taken. The technique was used to correctly classify SE carriage in 99% of the patients. Independent confirmation in a second cohort of DRB1-typed Dutch patients with RA showed that with DQA1 and DQB1 typing, only 2 out of 167 patients (1.2%) would have been incorrectly classified36.

Statistical analysis

Haplotypes for SNP in the TNF-LTA region and the IL10 gene were inferred by use of PHASE 2.0, which implements a Bayesian algorithm to estimate the haplotype frequencies (http://www.stat.washington.edu/stephens/software.html).

Differences in baseline characteristics between patients with severe and mild radiographic progression were analyzed with Student’s t test, Mann-Whitney U test, and chi-squared test, as appropriate. Logistic regression analyses were used to determine associations between radiographic severity and the carrier frequency of alleles and haplotypes. Results are presented as OR with 95% CI, and the p value. If a significant effect was found for a single SNP, logistic regression was used to correct for linkage disequilibrium between distinct alleles. Logistic regression was also used for the determination of confounding of baseline variables. P values < 0.05 were considered statistically significant. Statistical analyses were performed using SPSS 15.0 Software (SPSS, Chicago, IL, USA).

RESULTS

A total of 151 patients with UA were eligible for our study. A minority of the patients (32%) were classified as having severe radiographic progression and the remainder (68%) as mild radiographic progression. At baseline, the mean age and symptom duration were comparable for both groups (Table 1). The mean DAS28, median CRP, mean ESR, percentage IgM-RF positivity, and ACPA positivity were higher in the severe disease group. The severe group had a higher SHS at baseline. After 2 years of followup, the number of DMARD used was significantly lower in the mild group compared to the severe group, while 50% of the patients in the severe group and 18% in the mild group fulfilled the 1987 ACR criteria for RA at that time.

In a univariate analysis, the carrier frequency of TNF −308A allele was significantly lower in the severe group (OR 0.43, 95% CI 0.20–0.90, p = 0.02). Carrier frequencies of other TNF or LTA minor alleles did not differ between patients with severe and mild radiographic progression (Table 2). The SE frequency was significantly lower in carriers of the TNF −308A allele (p < 0.001). Focusing on the TNF-LTA haplotypes, only the carrier frequency of haplotype E, tagged by TNF −308A allele, was significantly lower in the severe group (Table 3). A strong linkage disequilibrium was found between the TNF −308A allele and HLA-DQA1*05-DQB1*02 haplotype: 72.1% of the TNF −308A carriers were carriers of the HLA-DQA1*05-DQB1*02 haplotype. After stratification for radiographic progression, similar percentages were found (mild 53.8% vs progressive 77.1%).

View this table:
  • View inline
  • View popup
Table 2.

TNF and LTA SNP carrier frequency and radiographic progression.

View this table:
  • View inline
  • View popup
Table 3.

TNF-LTA haplotype carrier frequency and radiographic progression in undifferentiated arthritis.

Table 4 shows the carrier frequencies of (combinations of) HLA-DQA1*-DQB1* haplotypes. The numbers of HLA-DR4-related SE copies (OR 4.24, 95% CI 2.05–8.79, p = 0.001) and DR1-, DR4-, or DR10-related SE copies (OR 3.78, 95% CI 1.66–8.60, p = 0.001) were positively associated with an increased risk of severe progression of radiographic damage. Carrier frequency of HLA-DQA1*05-DQB1*02 was significantly lower in the severe disease group (OR 0.30, 95% CI 0.13–0.71, p = 0.013).

View this table:
  • View inline
  • View popup
Table 4.

Haplotype HLA-DQA1* – DQB1* Carrier frequency in undifferentiated arthritis.

SNP in IL1 family genes and IL10 were similarly distributed among the groups (Table 5). The IL10 −1082A allele showed a trend toward a lower carrier frequency in the severe disease group compared to the mild group. Focusing on the IL10 haplotypes, only the carrier frequency of the GGC haplotype of the IL10 −2849G/A, IL10 −1082G/A, and IL10 −819C/T SNP was increased significantly in the severe group compared to the mild group (OR 2.84, 95% CI 1.40–5.75, p = 0.003; Table 6).

View this table:
  • View inline
  • View popup
Table 5.

Carrier frequencies of IL1 family and IL10 minor alleles and radiographic progression in undifferentiated arthritis.

View this table:
  • View inline
  • View popup
Table 6.

IL10 haplotype carriers and radiographic progression in undifferentiated arthritis.

In order to detect additive or synergistic effects or interaction between HLA-DQA1*05-DQB1*02 and the IL10 GGC haplotype, logistic regression was performed. The DQA1*05-DQB1*02 haplotype and the IL10 GGC haplotype were both independently associated with progression of radiographic damage. The IL10 GGC haplotype was positively associated, while the DQA1*05-DQB1*02 haplotype was negatively associated.

To explore whether variables measured at baseline act as confounders of the SNP association, multivariate logistic regression was performed. The number of SE, SHS at baseline, CRP at baseline, and the number of DMARD used were not confounders. But ACPA positivity, IgM-RF positivity, DAS28 at baseline, and sex were marked as confounders. In a multivariate logistic model with IL10 GGC haplotype and HLA-DQA1*05-DQB1*02 haplotype, adjusted for these 4 confounders, HLA-DQA1*05-DQB1*02 haplotype was no longer a significant contribution in the model (IL10 GGC haplotype: OR 7.79, 95% CI 2.19–29.01, p = 0.002; and HLA-DQA1*05-DQB1*02: OR 0.33, 95% CI 0.09–1.19, p = 0.091).

DISCUSSION

In patients with early UA, we have shown the IL10 GGC haplotype to be related to severe radiographic progression, in contrast with the DQA1*05-DQB1*02 haplotype [strictly DRB1*0301 (DR3) related]34,35, which is associated with mild progression of radiographic damage after 2 years. The TNF −308A allele was also associated with mild progression, but was not independent from the HLA-DQA1*05-DQB1*02 haplotype. The higher carrier frequency of the TNF −308A allele in the mild disease group was rather unexpected because carriers of the TNF −308A were described as having an increased TNF-α production17.

Contradictory results are reported of association between the TNF −308 SNP and erosive outcome in RA37,38. One study in only IgM-RF-seropositive patients with early RA described an association between the TNF −308 AA+GA genotypes and a higher radiographic progression rate over 5 years, adjusted for the presence of SE39, while our result is in accord with a reported association between the TNF −308GG genotype and erosions in RA40. Other studies found no association between TNF −308 polymorphisms and radiographic progression, probably because of use of the Larsen score, which is a less sensitive method in an early stage of the disease38,41. Similarly, in a recent prospective study of patients with early-onset RA, the erosive damage at 1 year was not influenced by this polymorphism42.

In our study, baseline characteristics such as tender and swollen joints and the number of DMARD taken during the 2 years of followup were similar between carriers and non-carriers of the TNF −308A allele. It therefore seems unlikely that a difference in treatment may account for the reported association between TNF −308A carriage and mild radiographic progression. Therefore, it is hard to explain why patients with this TNF −308A allele, which is known for its association with a high production of proinflammatory TNF-α and a higher radiographic progression in RA, would have milder progression in our UA group. The fact that the TNF −308A carrier frequency was increased in patients with mild UA might be explained by the linkage disequilibrium with the DQA1*05-DQB1*02 haplotype, which is associated with a mild disease and might overrule the effect of the TNF −308A allele.

The carrier frequency of the HLA-DR4-related SE copies and DR1-, DR4-, or DR10-related SE copies was positively associated with severe progression, which is well known, and was independent from ACPA status at baseline. The lower carrier frequency of the DQA1*0501-DQB1*02 haplotype (in very strong linkage disequilibrium with the HLA-DRB1*03 allele) in the severe disease group compared to the mild group might be explained by the absence of HLA alleles carrying the SE, which are known to be associated with a more severe disease, or by the presence of protective HLA-DQ haplotypes9,43. In contrast, it was reported that the frequency of HLA-DRB1*03 in 88 Finnish patients with RA was associated with features of severe disease, such as extraarticular disease (p < 0.01) and prostheses in large joints (p < 0.05), but this was only a small group with a different genetic background44.

The TNF −308A allele and DQA1*0501-DQB1*02 were not independently associated with radiographic progression; this linkage disequilibrium was described before in RA39. Further, HLA-DRB1*0301 was significantly associated with ACPA-negative RA, while the absence of ACPA is associated with less radiographic progression in early RA14,45. The results in our patients with early arthritis are different from an early RA population, but the association between carriage of the TNF −308A allele, supported by the linkage disequilibrium with the DQA1*0501-DQB1*02 haplotype (DRB1*0301-related), are in accord with other reports in RA.

The carrier frequencies of other TNF alleles at −238, −857, −863, and −1031 and the LTA alleles at +368 and +252 were comparable for both radiographic groups. Some studies reported higher frequencies of the TNF −238GG genotype in patients with RA with severe disease46,47, others reported no effect of the TNF −238 polymorphism on radiographic progression48. No associations were found for the SNP TNF −238, −857, −863, and RA, although in a Taiwanese population, ethnic differences may have accounted for these discrepancies49.

The SNP in other cytokine genes (IL1A −889, IL1B −31, IL1B +3953, IL1RN +2018, IL10 −2849, IL10 −1082, and IL10 −819) were not associated with radiographic progression in UA, which is in agreement with earlier results on IL1B −31, IL1B +3953, IL1RN +2018, and IL10 −1082 observed in patients with early RA50. Of note, Cantagrel, et al50 reported that patients who were SE-positive and also carried the minor allele IL1B +3953T showed an increased risk of erosive disease, while patients carrying this allele and who were SE-negative did not. We did not find that result in our study. Although these observations are very interesting, they have to be considered preliminary and will need to be confirmed.

Our results showed a significant association of the promoter IL10 GGC haplotype with severe radiographic damage, but showed only a nonsignificant association with the IL10 −1082 SNP. This association was independent of the other associations found with progression of radiographic damage and therefore the influence of the IL10 haplotype at an early stage of the disease might be high. A recent report described that the IL10 −1082A/G polymorphism was associated with the production of rheumatoid factor28 but not with radiographic progression in early RA. Others described an association between the IL10 −2849 A/G promoter polymorphism and autoantibody production and joint damage in RA26. The fact that in our study on radiographic progression in early UA the association with the IL10 promoter GGC haplotype reached significance but these polymorphisms individually did not might point to the presence of another allele with influence on the GGC haplotype in the haplotype block encompassing the IL10 gene51.

Our study has some limitations. First, the population size was limited, which with stratification in the analyses may cause a lack of power to detect differences between the groups, resulting in a type II error. Larger studies might detect the effects of the described SNP and haplotypes better. Second, we are aware that the associations found in this study have to be viewed with caution, because bias due to multiple testing might exist.

Radiographic progression in early UA seems to be enhanced in patients carrying the GGC haplotype of the IL10 −2849G/A, IL10 −1082G/A, or IL10 −819C/T SNP, as well as the SE, and less severe in patients carrying the DQA1*05-DQB1*02 haplotype or the TNF −308A allele.

Acknowledgments

The authors thank E. de Wit-Taen and V. van der Lugt, clinical research assistants, for collecting patient data, R. Heijmans for genotyping the SNP, and W. Bos for valuable comments on the manuscript.

Footnotes

  • Accepted for publication February 9, 2010.

REFERENCES

  1. 1.↵
    1. van der Horst-Bruinsma IE,
    2. Speyer I,
    3. Visser H,
    4. Breedveld FC,
    5. Hazes JM
    . Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084–8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mau W,
    2. Raspe HH,
    3. Mersjann H
    . Early arthritides: nosography, nosology, and diagnostic criteria. Scand J Rheumatol 1989;Suppl 79:3–12.
  3. 3.↵
    1. Wolfe F,
    2. Ross K,
    3. Hawley DJ,
    4. Roberts FK,
    5. Cathey MA
    . The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993;20:2005–9.
    OpenUrlPubMed
  4. 4.↵
    1. Jansen LM,
    2. van Schaardenburg D,
    3. van der Horst-Bruinsma IE,
    4. Dijkmans BA
    . One year outcome of undifferentiated polyarthritis. Ann Rheum Dis 2002;61:700–3.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Hitchon CA,
    2. Peschken CA,
    3. Shaikh S,
    4. El Gabalawy HS
    . Early undifferentiated arthritis. Rheum Dis Clin North Am 2005;31:605–26.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Morel J,
    2. Legouffe MC,
    3. Bozonat MC,
    4. Sany J,
    5. Eliaou JF,
    6. Daures JP,
    7. et al.
    Outcomes in patients with incipient undifferentiated arthritis. Joint Bone Spine 2000;67:49–53.
    OpenUrlPubMed
  7. 7.↵
    1. van der Helm-van Mil AH,
    2. Verpoort KN,
    3. Breedveld FC,
    4. Huizinga TW,
    5. Toes RE,
    6. de Vries RR
    . The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117–21.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Raychaudhuri S,
    2. Remmers EF,
    3. Lee AT,
    4. Hackett R,
    5. Guiducci C,
    6. Burtt NP,
    7. et al.
    Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008;40:1216–23.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Carrier N,
    2. Cossette P,
    3. Daniel C,
    4. Brum-Fernandes A,
    5. Liang P,
    6. Menard HA,
    7. et al.
    The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. Arthritis Rheum 2009;60:698–707.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Deighton CM,
    2. Walker DJ,
    3. Griffiths ID,
    4. Roberts DF
    . The contribution of HLA to rheumatoid arthritis. Clin Genet 1989;36:178–82.
    OpenUrlPubMed
  11. 11.↵
    1. Dieude P,
    2. Cornelis F
    . Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005;72:520–6.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Emery P,
    2. Salmon M,
    3. Bradley H,
    4. Wordsworth P,
    5. Tunn E,
    6. Bacon PA,
    7. et al.
    Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ 1992;305:1387–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mattey DL,
    2. Hassell AB,
    3. Dawes PT,
    4. Cheung NT,
    5. Poulton KV,
    6. Thomson W,
    7. et al.
    Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001;44:1529–33.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Irigoyen P,
    2. Lee AT,
    3. Wener MH,
    4. Li W,
    5. Kern M,
    6. Batliwalla F,
    7. et al.
    Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52:3813–8.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Feldmann M,
    2. Brennan FM,
    3. Maini RN
    . Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397–440.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Lipsky PE,
    2. van der Heijde DM,
    3. St. Clair EW,
    4. Furst DE,
    5. Breedveld FC,
    6. Kalden JR,
    7. et al.
    Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bouma G,
    2. Crusius JB,
    3. Oudkerk PM,
    4. Kolkman JJ,
    5. von Blomberg BM,
    6. Kostense PJ,
    7. et al.
    Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456–63.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bazzoni F,
    2. Beutler B
    . The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717–25.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Dayer JM
    . The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003;42 Suppl 2:ii3–10.
    OpenUrlAbstract
  20. 20.↵
    1. Arend WP
    . Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001;30(5 Suppl 2):1–6.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Dayer JM
    . Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? J Rheumatol 2002;29 Suppl 65:10–5.
    OpenUrlCrossRef
  22. 22.↵
    1. Carreira PE,
    2. Gonzalez-Crespo MR,
    3. Ciruelo E,
    4. Pablos JL,
    5. Santiago B,
    6. Gomez-Camara A,
    7. et al.
    Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. Arthritis Rheum 2005;52:3015–9.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Cox A,
    2. Camp NJ,
    3. Cannings C,
    4. di Giovine FS,
    5. Dale M,
    6. Worthington J,
    7. et al.
    Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999;8:1707–13.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Buchs N,
    2. di Giovine FS,
    3. Silvestri T,
    4. Vannier E,
    5. Duff GW,
    6. Miossec P
    . IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001;2:222–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Verhoef CM,
    2. van Roon JA,
    3. Vianen ME,
    4. Bijlsma JW,
    5. Lafeber FP
    . Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol 2001;28:1960–6.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Lard LR,
    2. van Gaalen FA,
    3. Schonkeren JJ,
    4. Pieterman EJ,
    5. Stoeken G,
    6. Vos K,
    7. et al.
    Association of the −2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003;48:1841–8.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Marinou I,
    2. Healy J,
    3. Mewar D,
    4. Moore DJ,
    5. Dickson MC,
    6. Binks MH,
    7. et al.
    Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007;56:2549–56.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Nemec P,
    2. Pavkova-Goldbergova M,
    3. Gatterova J,
    4. Fojtik Z,
    5. Vasku A,
    6. Soucek M
    . Association of the −1082 G/A promoter polymorphism of interleukin-10 gene with the autoantibodies production in patients with rheumatoid arthritis. Clin Rheumatol 2009;28:899–905.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Prevoo ML,
    2. van ’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL
    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. van der Heijde DM
    . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743–5.
    OpenUrlPubMed
  31. 31.↵
    1. Bruynesteyn K,
    2. van der Heijde DM,
    3. Boers M,
    4. Saudan A,
    5. Peloso P,
    6. Paulus H,
    7. et al.
    Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913–20.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Crusius JB
    . The immunogenetics of chronic inflammatory and autoimmune disease (PhD dissertation). Amsterdam: Vrije Universiteit; 2002.
  34. 34.↵
    1. Doherty DG,
    2. Vaughan RW,
    3. Donaldson PT,
    4. Mowat AP
    . HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids. Hum Immunol 1992;34:53–63.
    OpenUrlPubMed
  35. 35.↵
    1. Knipper AJ,
    2. Hakenberg P,
    3. Enczmann J,
    4. Kuhrober A,
    5. Kiesel U,
    6. Kogler G,
    7. et al.
    HLA-DRB1,3,4,5 and -DQB1 allele frequencies and HLA-DR/DQ linkage disequilibrium of 231 German caucasoid patients and their corresponding 821 potential unrelated stem cell transplants. Hum Immunol 2000;61:605–14.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. de Vries N,
    2. Tijssen H,
    3. van Riel PL,
    4. van de Putte LB
    . Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule. Arthritis Rheum 2002;46:921–8.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Brinkman BM,
    2. Huizinga TW,
    3. Kurban SS,
    4. van der Velde EA,
    5. Schreuder GM,
    6. Hazes JM,
    7. et al.
    Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997;36:516–21.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Lacki JK,
    2. Moser R,
    3. Korczowska I,
    4. Mackiewicz S,
    5. Muller W
    . TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol Int 2000;19:137–40.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Khanna D,
    2. Wu H,
    3. Park G,
    4. Gersuk V,
    5. Gold RH,
    6. Nepom GT,
    7. et al.
    Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 2006;54:1105–16.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Nemec P,
    2. Pavkova-Goldbergova M,
    3. Stouracova M,
    4. Vasku A,
    5. Soucek M,
    6. Gatterova J
    . Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 2008;27:59–65.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Barton A,
    2. Platt H,
    3. Salway F,
    4. Symmons D,
    5. Barrett E,
    6. Bukhari M,
    7. et al.
    Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 2004;63:280–4.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Reneses S,
    2. Gonzalez-Escribano MF,
    3. Fernandez-Suarez A,
    4. Pestana L,
    5. Davila B,
    6. Wichmann I,
    7. et al.
    The value of HLA-DRB1 shared epitope, −308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis. J Rheumatol 2009;36:1143–9.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. van der Horst-Bruinsma IE,
    2. Visser H,
    3. Hazes JM,
    4. Breedveld FC,
    5. Verduyn W,
    6. Schreuder GM,
    7. et al.
    HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999;60:152–8.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Hakala M,
    2. Silvennoinen-Kassinen S,
    3. Ikaheimo I,
    4. Isosomppi J,
    5. Tiilikainen A
    . HLA markers in a community-based rheumatoid arthritis series. Ann Med 1997;29:291–6.
    OpenUrlPubMed
  45. 45.↵
    1. Verpoort KN,
    2. van Gaalen FA,
    3. van der Helm-van Mil AH,
    4. Schreuder GM,
    5. Breedveld FC,
    6. Huizinga TW,
    7. et al.
    Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005;52:3058–62.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Kaijzel EL,
    2. van Krugten MV,
    3. Brinkman BM,
    4. Huizinga TW,
    5. van der Straaten T,
    6. Hazes JM,
    7. et al.
    Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4:724–33.
    OpenUrlPubMed
  47. 47.↵
    1. Fabris M,
    2. Di Poi E,
    3. D’Elia A,
    4. Damante G,
    5. Sinigaglia L,
    6. Ferraccioli G
    . Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002;29:29–33.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Fonseca JE,
    2. Cavaleiro J,
    3. Teles J,
    4. Sousa E,
    5. Andreozzi VL,
    6. Antunes M,
    7. et al.
    Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Res Ther 2007;9:R37.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Yen JH,
    2. Chen CJ,
    3. Tsai WC,
    4. Lin CH,
    5. Ou TT,
    6. Wu CC,
    7. et al.
    Tumor necrosis factor promoter polymorphisms in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2001;28:1788–92.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Cantagrel A,
    2. Navaux F,
    3. Loubet-Lescoulie P,
    4. Nourhashemi F,
    5. Enault G,
    6. Abbal M,
    7. et al.
    Interleukin-1 beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093–100.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Frazer KA,
    2. Ballinger DG,
    3. Cox DR,
    4. Hinds DA,
    5. Stuve LL,
    6. Gibbs RA,
    7. et al.
    A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851–61.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 7
1 Jul 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated Arthritis
JENNIE URSUM, MIGNON A.C. van der WEIJDEN, DIRKJAN van SCHAARDENBURG, AREND P.A. PRINS, BEN A.C. DIJKMANS, JOS W.R. TWISK, JAKOB B.A. CRUSIUS, IRENE E. van der HORST-BRUINSMA
The Journal of Rheumatology Jul 2010, 37 (7) 1431-1438; DOI: 10.3899/jrheum.090913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with Radiographic Progression in Undifferentiated Arthritis
JENNIE URSUM, MIGNON A.C. van der WEIJDEN, DIRKJAN van SCHAARDENBURG, AREND P.A. PRINS, BEN A.C. DIJKMANS, JOS W.R. TWISK, JAKOB B.A. CRUSIUS, IRENE E. van der HORST-BRUINSMA
The Journal of Rheumatology Jul 2010, 37 (7) 1431-1438; DOI: 10.3899/jrheum.090913
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
  • Clustering Patients With Gout Based on Comorbidities and Biomarkers: A Cross-Sectional Study
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire